Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Known cellular receptors for different AAV serotypes

From: Recent progress and considerations for AAV gene therapies targeting the central nervous system

Serotype Glycan recognitiona Coreceptor
AAV1 Neu5Acα2-3GalNAcβ1-4GlcNAc Unknown
AAV2 6-O- and N-sulfated heparin Fibroblast [108]/hepatocyte [109] growth factor receptor; laminin receptor [110]; integrin αVβ5 [111] and α5β1 [112]
AAV3 2-O- and N-sulfated heparin Hepatocyte growth factor receptor [113]; Laminin receptor [110]
AAV4 Galβ1-4GlcNAcβ1-2Manα1-6Manβ1-4GlcNAcβ1-4GlcNAc Unknown
AAV5 Neu5Acα2-3(6S)Galβ1-4GlcNAc Platelet-derived growth factor receptor [114]
AAV6 Neu5Acα2-3GalNAcβ1-4GlcNAc; N-sulfated heparin Epidermal growth factor receptor [115]
AAV7 Unknown Unknown
AAV8 Unknown Laminin receptor [110]
AAV9 Galactose [116] Laminin receptor [110]
  1. aAll glycan recognitions listed, except for AAV9, are from a study by Mietzsch et al. [117] and are more specific glycans compared to the original publications identifying the primary glycans recognized by each serotype